Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2657 (LASTR)
- Target
- LASTR
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
Long intergenic non-protein coding RNA 2657 (LASTR) is a stress-induced lncRNA that regulates pre-mRNA splicing by modulating the interaction of SART3 with U4 and U6 small nuclear ribonucleoproteins (snRNPs) during spliceosome cycling[1]. LASTR is upregulated in several epithelial cancers, including breast cancer and lung adenocarcinoma, particularly under hypoxic conditions and in response to activation of the JNK/c-JUN pathway[1]. It acts as a principal regulator of gene expression and chromatin state, and has emerging importance as both a prognostic biomarker and a potential therapeutic target in oncology, particularly due to its influence on tumor immune escape and immunotherapy resistance[1][5][7]. No approved drugs or direct LASTR-targeting therapies currently exist, but its diagnostic and therapeutic relevance in oncology continues to be actively explored[1][5].
- Other names
- LASTRLINC02657LINC02677long intergenic non-protein coding RNA 2657
02
Mechanism of action
Not applicable (no approved drugs targeting LASTR directly as of current data)
03
Biological functions
Regulation of pre-mRNA splicing (via modulation of SART3 and U4/U6 snRNPs)Chromatin dynamics and gene regulation (through broader lncRNA mechanisms)Stress-induced transcriptional regulationInfluences immune responses and tumor immune escape
04
Disease associations
Cancer (notably in hypoxic breast cancer, triple-negative breast cancer, and lung adenocarcinoma)Cancer immunotherapy resistance
05
Safety considerations
No specific safety concerns reported for targeting LASTR, but as a regulator of splicing and immune response, off-target effects may be a concern in future therapeutic development
06
Biomarkers
Prognostic biomarker for lung adenocarcinoma (LUAD) and potentially other epithelial malignanciesBiomarker for immune infiltration in tumors
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2657 (LASTR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2657 (LASTR).